Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Click here to view

Presentation

A Compact Zinc Finger Architecture for Highly Efficient Base Editing in Human Cells

Download PDF